Validation of an algorithm to identify antiretroviral-naïve status at time of entry into a large, observational cohort of HIV-infected patients

Pharmacoepidemiology and Drug Safety

Volumn 22, Issue 9, 2013, Pages 1019-1025

  Gandhi, Neel R ^a,b   Tate, Janet P ^c   Rodriguez Barradas, Maria C ^d   Rimland, David ^e   Goetz, Matthew Bidwell ^f   Gibert, Cynthia ^g   Brown, Sheldon T ^h   Mattocks, Kristin ^i,j   Justice, Amy C ^c  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g VETERANS AFFAIRS MEDICAL CENTER   (United States)

^h MOUNT SINAI SCHOOL OF MEDICINE   (United States)

ⁱ VA Central Western Massachusetts Healthcare System   (United States)

^j UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

more..

Author keywords

Antiretroviral therapy; Cohort studies; HIV infections drug therapy; HIV infections epidemiology; HIV 1; Pharmacoepidemiology

Indexed keywords

ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; RITONAVIR;

ADULT; ALGORITHM; ANTIVIRAL THERAPY; ARTICLE; COHORT ANALYSIS; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; OBSERVATIONAL STUDY; PREDICTIVE VALUE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; VIRUS LOAD;

ANTIRETROVIRAL THERAPY; COHORT STUDIES; HIV INFECTIONS/DRUG THERAPY; HIV INFECTIONS/EPIDEMIOLOGY; HIV-1; PHARMACOEPIDEMIOLOGY;

ALGORITHMS; ANTI-RETROVIRAL AGENTS; COHORT STUDIES; FEMALE; HIV INFECTIONS; HUMANS; MALE; MEDICAL RECORDS; MIDDLE AGED; OBSERVATIONAL STUDY AS TOPIC; PHARMACOEPIDEMIOLOGY; PREDICTIVE VALUE OF TESTS; QUESTIONNAIRES; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; VIRAL LOAD;

EID: 84882656965     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.3476     Document Type: Article

References (24)

1. Palella FJ, Jr., Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338: 853-860.
2. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med 1997; 337: 725-733.
3. Lucas GM, Eustace JA, Sozio S, et al. Highly active antiretroviral therapy and the incidence of HIV-1-associated nephropathy: a 12-year cohort study. AIDS 2004; 18: 541-546.
4. Egger M, May M, Chene G, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002; 360: 119-129.
5. Sterne JA, Hernan MA, Ledergerber B, et al. Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study. Lancet 2005; 366: 378-384.
6. Chen RY, Westfall AO, Mugavero MJ, et al. Duration of highly active antiretroviral therapy regimens. Clin Infect Dis 2003; 37: 714-722.
7. Fischer MJ, Wyatt CM, Gordon K, et al. Hepatitis C and the risk of kidney disease and mortality in veterans with HIV. J Acquir Immune Defic Syndr 2010; 53: 222-226.
8. Friis-Moller N, Reiss P, Sabin CA, et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007; 356: 1723-1735.
9. Kesselring AM, Wit FW, Sabin CA, et al. Risk factors for treatment-limiting toxicities in patients starting nevirapine-containing antiretroviral therapy. AIDS 2009; 23: 1689-1699.
10. Althoff KN, Justice AC, Gange SJ, et al. Virologic and immunologic response to HAART, by age and regimen class. AIDS 2010; 24: 2469-2479.
11. Greenbaum AH, Wilson LE, Keruly JC, et al. Effect of age and HAART regimen on clinical response in an urban cohort of HIV-infected individuals. AIDS 2008; 22: 2331-2339.
12. Grabar S, Kousignian I, Sobel A, et al. Immunologic and clinical responses to highly active antiretroviral therapy over 50 years of age. Results from the French Hospital Database on HIV. AIDS 2004; 18:2029-2038.
13. Choi AI, Rodriguez RA, Bacchetti P, et al. Racial differences in end-stage renal disease rates in HIV infection versus diabetes. J Am Soc Nephrol 2007; 18: 2968-2974.
14. Gange SJ, Kitahata MM, Saag MS, et al. Cohort profile: the north american AIDS cohort collaboration on research and design (NA-ACCORD). Int J Epidemiol 2007; 36: 294-301.
15. Zhou J, Kumarasamy N, Ditangco R, et al. The TREAT Asia HIV observational database: baseline and retrospective data. J Acquir Immune Defic Syndr 2005; 38: 174-179.
16. McGowan CC, Cahn P, Gotuzzo E, et al. Cohort profile: caribbean, central and south america network for HIV research (CCASAnet) collaboration within the international epidemiologic databases to evaluate AIDS (IeDEA) programme. Int J Epidemiol 2007; 36: 969-976.
17. Lang S, Mary-Krause M, Cotte L, et al. Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a case-control study nested within the French Hospital Database on HIV ANRS cohort CO4. Arch Intern Med 2010; 170: 1228-1238.
18. Fultz SL, Skanderson M, Mole LA, et al. Development and verification of a "virtual" cohort using the National VA Health Information System. Med Care 2006; 44: 25-30.
19. Braitstein P, Brinkhof MW, Dabis F, et al. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet 2006; 367: 817-824.
20. Boubaker K, Flepp M, Sudre P, et al. Hyperlactatemia and antiretroviral therapy: the Swiss HIV Cohort Study. Clin Infect Dis 2001; 33: 1931-1937.
21. Friis-Moller N, Sabin CA, Weber R, et al. Combination antisretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003; 349: 1993-2003.
22. Stenzel MS, Carpenter CC. The management of the clinical complications of antiretroviral therapy. Infect Dis Clin North Am 2000; 14: 851-878, vi
23. Gandhi NR, Skanderson M, Gordon KS, et al. Delayed presentation for human immunodeficiency virus (HIV) care among veterans: a problem of access or screening? Med Care 2007; 45: 1105-1109.
24. Justice AC, Dombrowski E, Conigliaro J, et al. Veterans Aging Cohort Study (VACS): overview and description. Med Care 2006; 44: 13-24.